1. |
Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries. Chin J Cancer Res, 2013, 25(1): 10-21.
|
2. |
Catalano MG, Fortunati N, Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne), 2012, 3: 40.
|
3. |
Caminha LS, Momesso DP, Vaisman F, et al. Longterm follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment. Clin Nucl Med, 2013, 38(10): 765-769.
|
4. |
高明, 滕卫平, 刘永峰, 等.甲状腺结节和分化型甲状腺癌诊治指南.中国肿瘤临床, 2012, 39(17): 1249-1272.
|
5. |
Sokilde R, Vincent M, Moller A K, et al. Efficient Identification of miRNAs for classification of tumor origin. J Mol Diagn, 2014, 16(1): 106-115.
|
6. |
Tomasetti M, Santarelli L, Neuzil J, et al. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion, 2014, 19 Pt A: 29-38.
|
7. |
Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type. Thyroid, 2011, 21(2): 125-134.
|
8. |
Waldman SA, Terzic A. MicroRNA signatures as diagnostic and therapeutic targets. Clin Chem, 2008, 54(6): 943-944.
|
9. |
李丹, 郭丽英. microRNA与乳腺癌浸润转移关系的研究进展.中国普外基础与临床杂志, 2014, 21(5): 654-657.
|
10. |
Braun J, Hüttelmaier S. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res, 2011, 4 Suppl 1: S1.
|
11. |
He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Prec Natl Acad Sci USA, 2005, 102(52): 19075-19080.
|
12. |
Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Revi, 2015, 81: 75-93.
|
13. |
杨良, 李航宇, 刘金钢. microRNA调控肿瘤微环境的研究进展.中国普外基础与临床杂志, 2015, 22(2): 251-255.
|
14. |
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med, 2014, 20(8): 460-469.
|
15. |
Qiu T, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett, 2014, 588(7): 1168-1177.
|
16. |
Brocato J, Chervona Y, Costa M. Molecular responses to hypoxia-inducible factor 1αand beyond. Mol Pharmacol, 2014, 85(5): 651-657.
|
17. |
Tan SB, Li J, Chen X, et al. Small molecule inhibitor of myogenic microRNAs leads to a discovery of miR-221/222-myoD-myomiRs regulatory pathway. Chem Biol, 2014, 21(10): 1265-1270.
|
18. |
Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett, 2014, 588(1): 99-104.
|
19. |
Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer, 2013, 108(2): 361-369.
|
20. |
姚廷敬, 彭德峰, 朱金海, 等.甲状腺癌miRNA-146与BRAF突变的相关性研究.淮海医药, 2013, 31(3): 189-191.
|
21. |
Eszlinger M, Krogdahl A, Münz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid, 2014, 24(2): 305-313.
|
22. |
Mazeh H, Levy Y, Mizrahi I, et al. Differentiating benign from mali-gnant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Sur Res, 2013, 180(2): 216-221.
|
23. |
陈晓敏, 曹国平, 陈琪. miR-221及miR-222在甲状腺结节针吸细胞活检组织中的表达水平.现代实用医学, 2013, 25(10): 1120-1122.
|
24. |
Pai R, Nehru GA, Samuel P, et al. Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues. Indian J Pathol Microbiol, 2012, 55(2): 158-162.
|
25. |
刘超, 戴璇璇, 周毅力, 等.甲状腺乳头状癌mir-221表达与BRAF突变的相关性研究.中国肿瘤, 2012, 21(4): 298-302.
|
26. |
Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
|
27. |
Lee JC, Zhao JT, Gundara J, et al. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222 Original Research Article. J Surg Res, 2015, 196(1): 39-48.
|
28. |
Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer, 2006, 13(2): 497-508.
|
29. |
Wojtas B, Ferraz C, Stokowy T, et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol, 2014, 388(1-2): 1-9.
|
30. |
Ihle MA, Trautmann M, Kuenstlinger H, et al. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol Oncol, 2015, 9(7): 1421-1433.
|
31. |
Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221and miR-222, both over expressed in human thyroid papillary carcinomas, regulate p27Kip1 proteinlevels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
|
32. |
Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6): 498-509.
|
33. |
张春智, 康春生, 浦佩玉, 等.反义microRNA-221与反义microRNA-222抑制人脑胶质瘤细胞的体外与体内生长.中华肿瘤杂志, 2009, 31(10): 721-726.
|
34. |
Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA21 concentrations in early and advanced breast cancer. Clin Chem, 2011, 57(1): 84-91.
|
35. |
Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non small cell lung cancer. Clin Oncol, 2010, 28(10): 1721-1726.
|